Analysis reveals that GLP-1 drugs' HbA1c improvement is partly but not entirely explained by weight loss, with significant direct glucose-lowering effects independent of body weight changes.
Both mechanisms matterGLP-1 drugs improve HbA1c through weight loss AND direct glucose-lowering effects — neither alone explains the full benefit
What the researchers found
Weight loss contributes to but does not fully explain GLP-1 drug HbA1c improvement. Significant direct glucose-lowering effects operate independently of weight change.
Why it matters
If GLP-1 drugs only worked through weight loss, cheaper weight-loss approaches might suffice. Demonstrating direct glucose-lowering effects justifies their use as diabetes drugs, not just weight-loss drugs.
The numbers in context
256 patients: exenatide (84), dulaglutide (99), semaglutide (73). 2.5-year follow-up. No other medication changes during the study period.
How the study worked
Analysis of weight loss and HbA1c change data from multiple GLP-1 RA clinical trials (exenatide, dulaglutide, semaglutide) to decompose the relative contributions of weight-dependent and weight-independent glucose-lowering mechanisms.
Who was studied
256 adults with T2DM treated with exenatide (84), dulaglutide (99), or semaglutide (73) for 2.5 years
What this study cannot tell us
Decomposing weight-dependent from weight-independent effects is methodologically challenging. Individual variation is large. The analysis uses aggregate trial data.
How to read the evidence
Strong evidence: analysis of multiple clinical trials decomposing weight-dependent and independent mechanisms.
When this study was published
Published in 2025. Resolves a fundamental question about GLP-1 drug mechanisms.
The bigger picture
This analysis resolves a key question: GLP-1 drugs are true diabetes drugs with direct glucose-lowering properties, not just weight-loss drugs that incidentally improve blood sugar. Both mechanisms — metabolic and weight — contribute to their remarkable efficacy.
Questions still open
- What proportion of HbA1c improvement comes from weight loss vs direct mechanisms?
- Do different GLP-1 drugs rely more heavily on weight loss vs direct glucose effects?
- Would GLP-1 drugs benefit lean T2D patients who have little weight to lose?
Common questions
Do GLP-1 drugs only work because of weight loss?
Will GLP-1 drugs help if I am not overweight?
Read the original research
Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.
Journal of diabetes, 17(1), e70054
Citation
Al-Badri, Marwa; Dhaver, Shilton; Hamdy, Osama. (2025). Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.. Journal of diabetes, 17(1), e70054. https://doi.org/10.1111/1753-0407.70054